ALK and neuroblastoma: A recent study of ALK aberrations in 1,596 diagnostic neuroblastomas showed that different ALK mutations confer differential oncogenic potential and sensitivity to Crizotinib, demonstrating the clinical relevance of mutational status for therapeutic stratification of ALK therapies for patients [6].